ClinicalTrials.gg
TerminatedNCT05743036Updated Aug 8, 2025

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

A Phase 1 interventional study of ZN-c3 and Encorafenib in Metastatic Colorectal Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. Terminated at 27 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

Why this study was terminated
Study terminated due to change in therapeutic landscape.

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 461 studies in Colorectal Neoplasms with a site in Spain — 96 open to participants now, 149 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Enrollment
341st of 404
44 · median 168
Started
2023
with 29 others
Phase 1
79 of 461
19 open now
Registered
355th of 461
by date

Among the 461 studies in Colorectal Neoplasms with a site in Spain, this one is the 341st largest by enrollment of the 404 interventional ones that give a count, is one of 30 that started in 2023, is one of 79 in phase 1, and was the 355th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

96 of the 461 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 461 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic Colorectal Cancer
  • CRC
  • BRAF V600E
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed Stage IV colorectal adenocarcinoma.
  • Documented evidence of a BRAF V600E mutation in tumor tissue or blood
  • Presence of per version 1.1 guidelines.
  • Disease progression after 1 or 2 previous systemic regimens for metastatic disease
  • Adequate bone marrow function
  • Adequate hepatic and renal function

Exclusion criteria

Exclusion Criteria:

  • Documented clinical disease progression or radiographic disease progression during the screening period
  • .
  • Symptomatic .
  • Presence of acute or chronic pancreatitis.
  • Unable to swallow, retain, and absorb oral medications.
  • cardiovascular diseases
  • Evidence of active noninfectious pneumonitis.
  • Evidence of active and uncontrolled bacterial or viral infection, within 2 weeks prior to start of any of the study interventions
  • Participants with known positivity for
  • Active or infection
  • Concurrent or previous other within 2 years of study entry
  • Has had an allogeneic tissue/solid organ transplant
  • Pregnant or females of who have a positive β-hCG laboratory test result within 14 days prior to enrollment or is breastfeeding
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Participants will receive different doses of ZN-c3 in combination with different doses of Encorafenib and a fixed dose of Cetuximab

    Drug: ZN-c3 · Drug: Encorafenib · Drug: Cetuximab

  • Experimental
    Dose Expansion

    Participants will receive recommended dose of ZN-c3 and encorafenib as determined in dose escalation phase in combination with cetuximab

    Drug: ZN-c3 · Drug: Encorafenib · Drug: Cetuximab

Interventions

  • DrugZN-c3

    ZN-c3 tablet by mouth, in combination with encorafenib

  • Encorafenib capsule by mouth, in combination with ZN-c3

    Also known as: BRAFTOVI®

  • Infusion

    Also known as: ERBITUX®

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase - Incidence of Dose Limiting Toxicities (DLTs)

    DLTs defined as treatment-related AEs occurring within the first 29 days after the start of any study treatment that in the opinion of the investigator cannot be reasonably attributed to the participant's underlying disease, concomitant medications, or pre-existing conditions.

    Time frame: From Lead-in Day -1 to Cycle 1 Day 28

  2. Dose Expansion Phase - Objective response rate (ORR)

    ORR defined as the proportion of participants who achieves a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator per RECIST Version 1.1.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

Secondary outcomes

  1. Dose Escalation Phase - Incidence and severity of adverse events (AEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  2. Proportion of participants with dose interruptions due to AEs in Dose Escalation Phase

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  3. Proportion of participants with dose modifications due to AEs in Dose Escalation Phase

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  4. Proportion of participants with discontinuations due to AEs in Dose Escalation Phase

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  5. Dose Escalation Phase - Objective response rate (ORR)

    ORR defined as the proportion of participants who achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) per RECIST Version 1.1.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  6. Dose Escalation Phase - Duration of Response (DOR)

    DOR defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  7. Dose Escalation Phase - Progression Free Survival (PFS)

    PFS defined as the time from the first dose to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  8. Dose Escalation Phase - Disease Control Rate (DCR)

    DCR defined as the proportion of participants with BOR of CR, PR, or stable disease (SD), per RECIST version 1.1.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  9. Dose Escalation Phase - Time to Response (TTR)

    TTR defined as the time from first dose to first radiographic evidence of response (CR or PR) per RECIST version 1.1.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  10. Dose Escalation - ZN-c3 plasma exposure: AUC

    Time frame: From lead in day -1 visit through Cycle 1 Day 15

  11. Dose Escalation - ZN-c3 plasma exposure: Cmax

    Time frame: From lead in day -1 visit through Cycle 1 Day 15

  12. Dose Escalation - ZN-c3 plasma exposure: Tmax

    Time frame: From lead in day -1 visit through Cycle 1 Day 15

  13. Dose Escalation - Encorafenib plasma exposure: AUC

    Time frame: From lead in day -1 visit through Cycle 1 Day 15

  14. Dose Escalation - Encorafenib plasma exposure: Cmax

    Time frame: From lead in day -1 visit through Cycle 1 Day 15

  15. Dose Escalation - Encorafenib plasma exposure: Tmax

    Time frame: From lead in day -1 visit through Cycle 1 Day 15

  16. Dose Expansion Phase - Duration of Response (DOR)

    DOR defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  17. Dose Expansion Phase - Progression Free Survival (PFS)

    PFS defined as the time from the first dose to the earliest documented disease progression per RECIST version 1.1, or death due to any cause.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  18. Dose Expansion Phase - Disease Control Rate (DCR)

    DCR defined as the proportion of participants with BOR of CR, PR, or stable disease (SD), per RECIST version 1.1.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  19. Dose Expansion Phase - Time to Response (TTR)

    TTR defined as the time from first dose to first radiographic evidence of response (CR or PR) per RECIST version 1.1.

    Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

  20. Dose Expansion Phase - Incidence and severity of adverse events (AEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  21. Proportion of participants with dose interruptions due to AEs in Dose Expansion Phase

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  22. Proportion of participants with dose modifications due to AEs in Dose Expansion Phase

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  23. Proportion of participants with discontinuations due to AEs in Dose Expansion Phase

    Time frame: From first dose of any study intervention through 28 days after the last dose of any study intervention

  24. Dose Expansion - ZN-c3 in combination with combination with E+C plasma exposure: AUC

    Time frame: Lead in day 7

  25. Dose Expansion - ZN-c3 in combination with combination with E+C plasma exposure: Cmax

    Time frame: Lead in day 7

  26. Dose Expansion - ZN-c3 in combination with combination with E+C plasma exposure: Tmax

    Time frame: Day 7

  27. Dose Expansion - Encorafenib in combination with ZN-c3 and cetuximab plasma exposure: AUC

    Time frame: Cycle 1 Day 15

  28. Dose Expansion - Encorafenib in combination with ZN-c3 and cetuximab plasma exposure: Cmax

    Time frame: Cycle 1 Day 15

  29. Dose Expansion - Encorafenib in combination with ZN-c3 and cetuximab plasma exposure: Tmax

    Time frame: Cycle 1 Day 15

  30. Dose Expansion - ZN-c3 plasma exposure: AUC

    Time frame: Cycle 1 Day 15

  31. Dose Expansion - ZN-c3 plasma exposure: Cmax

    Time frame: Cycle 1 Day 15

  32. Tumor tissue BRAF V600E mutational status

    Time frame: From lead in day 1 visit through the last dose of any study intervention, up to 12 months

07

Study locations

27 sites
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Alliance for Multispecialty Research, LLC
    Merriam, Kansas 66204, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Hämatologie- Onkologie im Zentrum MVZ GmbH
    Augsburg, Bavaria 86150, Germany
  • Klinikum der Universität München Großhadern
    Munich, Bavaria 81377, Germany
  • Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie
    Munich, Bavaria 81737, Germany
  • Institut für Klinisch Onkologische Forschung
    Frankfurt am Main, Hesse 60488, Germany
  • DRK Kliniken Berlin - Köpenick
    Berlin, State of Berlin 12559, Germany
  • Semmelweis University-Department of Internal Medicine and Oncology
    Budapest, Budapest 1083, Hungary
  • Clinexpert Kft. Bugat Pal Korhaz
    Gyöngyös, 3200, Hungary
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale
    Naples, Campania 80131, Italy
  • IRCCS Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Foggia 71013, Italy
  • Istituto Europeo di Oncologia
    Milan, Milano 20141, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, Milano 20162, Italy
  • AOUI Verona
    Verona, Veneto 37126, Italy
  • Szpital Uniwersytecki w Krakowie
    Krakow, Lesser Poland Voivodeship 31-501, Poland
  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
    Krakow, Lesser Poland Voivodeship 31-826, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
    Warsaw, Masovian Voivodeship 02-034, Poland
  • Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
    Opole, Opole Voivodeship 45-061, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
  • Parc de Salut Mar - Hospital del Mar
    Barcelona, Catalonia 08003, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, Cordoba 14004, Spain
  • Hospital Universitario La Paz
    Madrid, Madrid 28046, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, Madrid 28222, Spain
  • Fundación Instituto Valenciano de Oncología
    Valencia, Valenciana, Comunitat 46009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jul 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 24, 2023
StartActual
Feb 27, 2023
Primary completionActual
Jul 16, 2024
CompletionActual
Jul 9, 2025
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743036
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Feb 27, 2023
Primary completion
Jul 16, 2024
Completion
Jul 9, 2025
Last update
Aug 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azenosertib

Start the discussion